- Home
- RFL vs EQ Comparison
RFL vs EQ Comparison
Compare RFL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- EQ
- Stock Information
- Founded
- RFL 2017
- EQ 2017
- Country
- RFL United States
- EQ United States
- Employees
- RFL N/A
- EQ N/A
- Industry
- RFL Real Estate
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- EQ Health Care
- Exchange
- RFL Nasdaq
- EQ Nasdaq
- Market Cap
- RFL 48.4M
- EQ 39.0M
- IPO Year
- RFL N/A
- EQ 2018
- Fundamental
- Price
- RFL $1.84
- EQ $0.71
- Analyst Decision
- RFL
- EQ Buy
- Analyst Count
- RFL 0
- EQ 2
- Target Price
- RFL N/A
- EQ $5.00
- AVG Volume (30 Days)
- RFL 26.3K
- EQ 311.1K
- Earning Date
- RFL 12-12-2024
- EQ 11-13-2024
- Dividend Yield
- RFL N/A
- EQ N/A
- EPS Growth
- RFL N/A
- EQ N/A
- EPS
- RFL N/A
- EQ N/A
- Revenue
- RFL $637,000.00
- EQ $45,914,000.00
- Revenue This Year
- RFL N/A
- EQ N/A
- Revenue Next Year
- RFL N/A
- EQ N/A
- P/E Ratio
- RFL N/A
- EQ N/A
- Revenue Growth
- RFL 128.32
- EQ 7.70
- 52 Week Low
- RFL $1.29
- EQ $0.48
- 52 Week High
- RFL $2.50
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- RFL 46.69
- EQ 39.09
- Support Level
- RFL $1.74
- EQ $0.68
- Resistance Level
- RFL $1.96
- EQ $0.89
- Average True Range (ATR)
- RFL 0.10
- EQ 0.11
- MACD
- RFL -0.01
- EQ -0.03
- Stochastic Oscillator
- RFL 40.00
- EQ 5.49
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.